These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38881923)

  • 21. Comprehensive analysis of tumor necrosis factor-α-inducible protein 8-like 2 (TIPE2): A potential novel pan-cancer immune checkpoint.
    Bai KH; Zhang YY; Li XP; Tian XP; Pan MM; Wang DW; Dai YJ
    Comput Struct Biotechnol J; 2022; 20():5226-5234. PubMed ID: 36187930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pan-cancer genetic analysis of disulfidptosis-related gene set.
    Liu H; Tang T
    Cancer Genet; 2023 Nov; 278-279():91-103. PubMed ID: 37879141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disulfidptosis-related gene
    Zhu J; Ge H; Chen Y; Zhang S; Wu J; Nai W; Min L
    Transl Cancer Res; 2024 Sep; 13(9):5064-5072. PubMed ID: 39430814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ferroptosis regulator SLC7A11 is a prognostic marker and correlated with PD-L1 and immune cell infiltration in liver hepatocellular carcinoma.
    Liang Y; Su S; Lun Z; Zhong Z; Yu W; He G; Wang Q; Wang J; Huang S
    Front Mol Biosci; 2022; 9():1012505. PubMed ID: 36267158
    [No Abstract]   [Full Text] [Related]  

  • 25. Integrative omics analysis reveals relationships of genes with synthetic lethal interactions through a pan-cancer analysis.
    Guo L; Li S; Qian B; Wang Y; Duan R; Jiang W; Kang Y; Dou Y; Yang G; Shen L; Wang J; Liang T
    Comput Struct Biotechnol J; 2020; 18():3243-3254. PubMed ID: 33240468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation analysis of disulfidptosis-related gene signatures with clinical prognosis and immunotherapy response in sarcoma.
    Xu J; Guo K; Sheng X; Huang Y; Wang X; Dong J; Qin H; Wang C
    Sci Rep; 2024 Mar; 14(1):7158. PubMed ID: 38531930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-cell disulfidptosis regulator patterns guide intercellular communication of tumor microenvironment that contribute to kidney renal clear cell carcinoma progression and immunotherapy.
    Xu K; Li D; Qian J; Zhang Y; Zhang M; Zhou H; Hou X; Jiang J; Zhang Z; Sun H; Shi G; Dai H; Liu H
    Front Immunol; 2024; 15():1288240. PubMed ID: 38292868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disulfidptosis-related genes of prognostic signature and immune infiltration features in hepatocellular carcinoma supported by bulk and single-cell RNA sequencing data.
    Wang Y; Yuan Z; Zhu Q; Ma J; Lu Q; Xiao Z
    J Gastrointest Oncol; 2024 Feb; 15(1):377-396. PubMed ID: 38482234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leveraging a gene signature associated with disulfidptosis identified by machine learning to forecast clinical outcomes, immunological heterogeneities, and potential therapeutic targets within lower-grade glioma.
    Zhou Y; Cao Y; Liu W; Wang L; Kuang Y; Zhou Y; Chen Q; Cheng Z; Huang H; Zhang W; Jiang X; Wang B; Ren C
    Front Immunol; 2023; 14():1294459. PubMed ID: 38162649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring the role of the disulfidptosis-related gene SLC7A11 in adrenocortical carcinoma: implications for prognosis, immune infiltration, and therapeutic strategies.
    Liu T; Ren Y; Wang Q; Wang Y; Li Z; Sun W; Fan D; Luan Y; Gao Y; Yan Z
    Cancer Cell Int; 2023 Nov; 23(1):259. PubMed ID: 37919768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploring the role of disulfidptosis-related signatures in immune microenvironment, prognosis and therapeutic strategies of cervical cancer.
    Jin T; Yin T; Xu R; Liu H; Yuan S; Xue Y; Zhang J; Wang H
    Transl Oncol; 2024 Jun; 44():101938. PubMed ID: 38492499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer.
    Pan G; Xie H; Xia Y
    Heliyon; 2024 Feb; 10(3):e25573. PubMed ID: 38356551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pan-Cancer Analysis on the Oncogenic Role of Programmed Cell Death 10.
    Sun N; Li C; Teng Y; Deng Y; Shi L
    J Oncol; 2022; 2022():1242658. PubMed ID: 36276268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrated multiomic analysis reveals disulfidptosis subtypes in glioblastoma: implications for immunotherapy, targeted therapy, and chemotherapy.
    Yang X; Cai Z; Wang C; Jiang C; Li J; Chen F; Li W
    Front Immunol; 2024; 15():1362543. PubMed ID: 38504986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying disulfidptosis subtypes in hepatocellular carcinoma through machine learning and preliminary exploration of its connection with immunotherapy.
    Chen G; Zhang G; Zhu Y; Wu A; Fang J; Yin Z; Chen H; Cao K
    Cancer Cell Int; 2024 Jun; 24(1):194. PubMed ID: 38831301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of disulfidptosis and periodontitis: New insights and clinical significance.
    Fan Y; Liu W; Qi L; Zhao Q; Li S; Zou H; Kong C; Li Z; Ren J; Liu Z; Wang B
    Arch Oral Biol; 2024 Oct; 166():106046. PubMed ID: 38991331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cross-talk between disulfidptosis and immune check point genes defines the tumor microenvironment for the prediction of prognosis and immunotherapies in glioblastoma.
    Zhou Y; Qin X; Hu Q; Qin S; Xu R; Gu K; Lu H
    Sci Rep; 2024 Feb; 14(1):3901. PubMed ID: 38365809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune checkpoint PTPN2 predicts prognosis and immunotherapy response in human cancers.
    Tang X; Sui X; Liu Y
    Heliyon; 2023 Jan; 9(1):e12873. PubMed ID: 36685446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pan-cancer analysis of necroptosis-related gene signature for the identification of prognosis and immune significance.
    Ma J; Jin Y; Gong B; Li L; Zhao Q
    Discov Oncol; 2022 Mar; 13(1):17. PubMed ID: 35312867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multi-omics analysis of disulfidptosis regulators and therapeutic potential reveals glycogen synthase 1 as a disulfidptosis triggering target for triple-negative breast cancer.
    Xie J; Deng X; Xie Y; Zhu H; Liu P; Deng W; Ning L; Tang Y; Sun Y; Tang H; Cai M; Xie X; Zou Y
    MedComm (2020); 2024 Mar; 5(3):e502. PubMed ID: 38420162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.